Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies
- PMID: 33353828
- DOI: 10.1016/j.ejso.2020.12.010
Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies
Abstract
Introduction: The efficacy of neoadjuvant chemotherapy (NAC) for advanced gastric cancer (GC) has recently been revealed. The use of tumor regression grade (TRG) has also been reported, where TRG has been positively correlated with prognosis. However, previous studies included several types of GC and treatments. The prognostic value of TRG in a specific population has not been well investigated. Therefore, a meta-analysis of studies on gastric adenocarcinomas treated with NAC that evaluate the prognostic impact of TRG on overall survival (OS) must be conducted to provide more accurate evidence.
Methods: A meta-analysis of studies reporting gastric cancer/gastroesophageal junction (GC/GEJ) adenocarcinoma treated with NAC was performed. Studies that calculate the number of responders and non-responders were considered eligible. The risk ratio (RR) was obtained from the eligible studies, and a random-effects model was used for pooled analysis.
Results: Fourteen studies, which included a total of 1660 patients, were included in the current study. The responders showed better OS (RR: 0.53, 95% confidence interval (CI): 0.46-0.60, P < 0.001). All subgroup analyses (Asian vs. non-Asian populations, different TRGs, GC/GEJ vs. GC) also revealed the statistical dominance of better TRG over better OS. However, the possibility of some publication bias remained.
Conclusions: In this meta-analysis, better TRG was associated with better OS. However, the histology, configuration, and location of GC varied. Hence, a more subdivided analysis is recommended to obtain more solid evidence.
Keywords: Gastric adenocarcinoma; Neoadjuvant chemotherapy; Tumor regression grade.
Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Similar articles
-
Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.BMC Gastroenterol. 2017 Mar 14;17(1):41. doi: 10.1186/s12876-017-0598-5. BMC Gastroenterol. 2017. PMID: 28292272 Free PMC article.
-
Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.J Surg Oncol. 2021 Dec;124(8):1356-1364. doi: 10.1002/jso.26669. Epub 2021 Sep 13. J Surg Oncol. 2021. PMID: 34515995
-
Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response.Cancer Chemother Pharmacol. 2019 Sep;84(3):635-646. doi: 10.1007/s00280-019-03893-4. Epub 2019 Jun 22. Cancer Chemother Pharmacol. 2019. PMID: 31230156
-
Oxaliplatin in perioperative chemotherapy for gastric and gastroesophageal junction (GEJ) adenocarcinoma.Expert Rev Gastroenterol Hepatol. 2019 Apr;13(4):285-291. doi: 10.1080/17474124.2019.1573143. Epub 2019 Feb 4. Expert Rev Gastroenterol Hepatol. 2019. PMID: 30791774 Review.
-
Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma.Cancer Med. 2016 Dec;5(12):3464-3474. doi: 10.1002/cam4.941. Epub 2016 Oct 24. Cancer Med. 2016. PMID: 27774774 Free PMC article. Review.
Cited by
-
Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: a real-world study.BMC Cancer. 2023 Oct 18;23(1):996. doi: 10.1186/s12885-023-11508-8. BMC Cancer. 2023. PMID: 37853387 Free PMC article.
-
Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis.Ann Surg Oncol. 2023 Jun;30(6):3594-3602. doi: 10.1245/s10434-023-13143-w. Epub 2023 Feb 16. Ann Surg Oncol. 2023. PMID: 36795255
-
Response Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Cancer.Cancers (Basel). 2023 Apr 15;15(8):2318. doi: 10.3390/cancers15082318. Cancers (Basel). 2023. PMID: 37190246 Free PMC article.
-
ASO Author Reflections: Neoadjuvant Chemotherapy Combined with Immunotherapy is a Promising Strategy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.Ann Surg Oncol. 2024 Nov;31(12):8179-8180. doi: 10.1245/s10434-024-16152-5. Epub 2024 Aug 30. Ann Surg Oncol. 2024. PMID: 39212861 No abstract available.
-
Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial.Nat Commun. 2024 Jan 2;15(1):41. doi: 10.1038/s41467-023-44309-5. Nat Commun. 2024. PMID: 38167806 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous